健康元药业集团股份有限公司2024年第三季度报告（英文版）

Joincare Pharmaceutical Group Industry Co., Ltd. 2024 Third Quarterly Report 1 / 13 Stock Code: 600380 Stock Short Name: 健康元 Joincare Pharmaceutical Group Industry Co., Ltd. 2024 Third Quarterly Report The Board of Directors and all Directors of the Company hereby warrant that there are no false representations, misleading statements or material omissions contained in this announcement and accept legal responsibility for the truthfulness, accuracy and completeness of the contents hereof. IMPORTANT NOTICE:  The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior management of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of this quarterly report, and that there are no false representations, misleading statements or material omissions contained herein, and severally and jointly accept legal responsibility.  The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-charge of the accounting department (the head of the accounting department) hereby warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.  Whether the third quarterly financial statements have been audited. □Yes √No I. MAJOR FINANCIAL DATA (I) Major Accounting Data and Financial Indicators Unit: Yuan Currency: RMB Item For the Reporting Period YoY change (%) From the beginning of the year to the end of the Reporting Period YoY change (%) Revenues 3,664,194,805.57 -6.80 11,898,828,905.02 -5.95 Net profit attributable to Shareholders of the listed company 335,135,597.05 24.95 1,111,560,063.92 2.58 Joincare Pharmaceutical Group Industry Co., Ltd. 2024 Third Quarterly Report 2 / 13 Net profit attributable to Shareholders of the listed company after deduction of extraordinary gain and loss 311,474,846.35 16.45 1,073,381,416.07 2.30 Net cash flow from operating activities N/A N/A 2,613,605,501.06 6.25 Basic earnings per share (RMB/share) 0.18 26.01 0.59 4.63 Diluted earnings per share (RMB/share) 0.18 26.79 0.59 4.97 Weighted average return on net assets (%) 2.32 Increased by 0.39 percentage points 7.82 Decreased by 0.40 percentage points As at the end of the Reporting Period As at the end of the previous year Change in the ending amount of the Reporting Period to that of the previous year (%) Total assets 36,172,500,281.87 36,358,126,258.82 -0.51 Net assets attributable to Shareholders of the listed company 14,487,774,610.56 13,755,901,924.06 5.32 Notes: 1. The “Reporting Period” represents the 3-month period from the beginning to the end of this quarter, the same below. 2. From January to September 2024, the Company’s Chemical pharmaceuticals achieved revenues of RMB5,879 million, representing a year-on-year decrease of 10.55%. Among them, revenues from gonadotropic hormones products reached RMB2,308 millio